Lafeuillade Bruno, Eb François, Ounnoughene Nadra, Petermann Rachel, Daurat Gérald, Huyghe Gérard, Vo Mai Mai-Phuong, Caldani Cyril, Rebibo Danielle, Weinbreck Pierre
Direction of Advanced Therapies, Human Products and Vaccines, French National Agency of Medicine and Health Products Safety-ANSM (ex Afssaps), Saint-Denis, France.
Transfusion. 2015 Mar;55(3):636-46. doi: 10.1111/trf.12883. Epub 2014 Sep 26.
Regarding blood safety, transfusion-transmitted bacterial infection (TTBI) remains the most frequent infectious risk. The incidence of these episodes needs to be assessed and updated frequently to accurately manage this risk.
TTBIs were reported by the French network of local correspondents in each hospital and blood center. The regional coordinator managed the investigation. A multidisciplinary expert group from the French National Agency of Medicine and Health Products Safety (ANSM) analyzed each TTBI according to a standardized scale of imputability and severity. Only cases with likely or certain imputability are reported in this study.
In France, 18.0 × 10(6) red blood cell (RBC) products, 1.94 × 10(6) platelet concentrates (PCs), and 2.44 × 10(6) fresh-frozen plasma units were transfused throughout 2000 to 2008. The incidence of TTBI was 2.45, 24.7, and 0.39 per million blood components (BCs), PCs, and RBCs, respectively. For PCs, the incidences of severe (vital threat or death) and fatal TTBI were 13.4 and 5.14 per million, respectively. PCs were responsible for 87% of TTBIs. A total of 66.7% of the implicated bacteria were Gram positive, most of them belonging to the normal skin flora. A total of 33.3% of the other implicated bacteria were Gram negative.
The French hemovigilance system provides an accurate estimate of the TTBI incidence during a period with diversion and improving skin disinfection but without bacterial detection screening. This tool would be able to evaluate further additional safety procedures like bacterial screening and pathogen reduction technology.
关于血液安全,输血传播细菌感染(TTBI)仍然是最常见的感染风险。需要经常评估和更新这些事件的发生率,以准确管理此风险。
法国各医院和血液中心的当地通讯员网络报告TTBI事件。区域协调员负责调查。法国国家药品与健康产品安全局(ANSM)的一个多学科专家组根据标准化的可归责性和严重程度量表对每例TTBI进行分析。本研究仅报告可能或肯定可归责的病例。
在法国,2000年至2008年期间共输注了18.0×10⁶单位红细胞(RBC)制品、1.94×10⁶单位血小板浓缩物(PC)和2.44×10⁶单位新鲜冰冻血浆。每百万血液成分(BC)、PC和RBC中TTBI的发生率分别为2.45、24.